RecruitingPhase 3NCT06512883

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS)

Sponsor

AstraZeneca

Enrollment

14 participants

Start Date

Apr 17, 2025

Study Type

INTERVENTIONAL

Conditions

Eosinophilic Granulomatosis With Polyangiitis (EGPA)Hypereosinophilia Syndrome (HES)

Summary

The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.

Eligibility

Min Age: 6 YearsMax Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Benralizumab for people with eosinophilic granulomatosis with polyangiitis (egpa) and hypereosinophilia syndrome (hes). The study is currently recruiting participants at 15 locations. People eligible for this study include aged 6 Years to 17 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBenralizumab

Benralizumab will be administered as SC injection on Q4W.

Locations(15)

Research Site

Aurora, Colorado, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Highland Hills, Ohio, United States

Research Site

São Paulo, Brazil

Research Site

Toronto, Ontario, Canada

Research Site

Lille, France

Research Site

Montpellier, France

Research Site

Ahmedabad, India

Research Site

Petah Tikva, Israel

Research Site

Guadalajara, Mexico

Research Site

Rotterdam, Netherlands

Research Site

Kielce, Poland

Research Site

Warsaw, Poland

Research Site

Altındağ, Turkey (Türkiye)

Research Site

Istanbul, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06512883

Related Trials

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

NCT0300432610 locations

Vasculitis Pregnancy Registry

NCT025935651 location